Actemra IV (tocilizumab) / Roche, JW Pharma - LARVOL DELTA

GLOFITAMAB COMBINED WITH R-CHOP OR POLA-R-CHP IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA: FINAL RESULTS FROM THE NP40126 STUDY (ICML 2025) - P1, P3 | "Introduction: Glofitamab (Glofit), a CD20xCD3 T-cell engaging bispecific antibody, showed promising efficacy when combined with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or Pola-R-CHP (polatuzumab vedotin substituting vincristine in R-CHOP) in an open-label, multicenter Phase 1b trial (NCT03467373)...Cytokine release syndrome occurred in 11% of Glofit+R-CHOP- and 13% of Glofit+Pola-R-CHP-treated pts; all were Gr 1/2 (by ASTCT criteria) and resolved; 22.2% of pts received tocilizumab (all in the Glofit+R-CHOP cohort)... This analysis of Glofit with R-CHOP or Pola-R-CHP confirmed early promising results with high rates of CMR, durable responses, and manageable safety in pts with 1L DLBCL. The ongoing Phase 3 SKYGLO study (NCT06047080) will further evaluate the efficacy and safety of Glofit+Pola-R-CHP versus Pola-R-CHP."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study (ASH 2025) - P1/2 | "Whileadvances such as BCMA-directed CAR T-cell therapy have improved outcomes, challenges persist,including disease relapse, treatment toxicities (CRS, ICANS, and non-ICANS neurotoxicities), and access.AZD0120 (formerly GC012F) is a first-in-class autologous BCMA/CD19 dual-targeting CAR T-cell therapyusing the FasTCAR rapid manufacturing platform that preserves the naive and central memory T-cellphenotypes with marked in vivo proliferative capacity...The median age was 64 y (range 44–78), median pLOT was 4 (range 3–7), 72% were triple-classrefractory, 20% had prior BCMA CAR T-cell therapy, 4% had prior teclistamab, 28% had high-riskcytogenetic features [del(13q), del(17p13), t(4; 14), t(14; 16), amp(1q)], and 8% had extramedullaryplasmacytomas...Median timeto CRS onset (DL1/DL2) was 9 d (range 2–11), with a median duration of 2 d (range 1–4); 12 pts (48%)received tocilizumab for CRS management and 12% received dexamethasone... Preliminary phase 1b results..."

CAR T-Cell Therapy • Clinical • P1/2 data • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Immunology • Multiple Myeloma • Plasmacytoma

A dual targeting BCMA and CD19 fastcar-t (GC012F/AZD0120) as first-line therapy for newly diagnosed multiple myeloma (ASH 2025) - P1, P1/2 | "Here, we report the combined data of these twostudies to provide long term follow up data of GC012F/AZD0120 in NDMM pts.Methods Eligible NDMM pts received a single infusion of GC012F/AZD0120 following two cycles lenalidomide,bortezomib and dexamethasone (RVd) induction therapy...GC012F/AZD0120 was administered at 4 dose levels:1x105/kg (n=1), 1.5x105/kg (n=3), 2x105/kg (n=4), or 3x105/kg (n=22) after a standard 3-daylymphodepletion regimen of fludarabine and cyclophosphamide...3 pts were treated with one dose of tocilizumab and 1 pt was treated with one dose oftocilizumab and corticosteroids...These promising results highlight the potential ofGC012F/AZD0120 CAR-T therapy for treating NDMM patients with HR features and transplant ineligibleNDMM pts. Further research with a larger patient population and extended follow-up is needed tovalidate these findings and address this critically unmet medical need."

Clinical • Hematological Malignancies • Inflammation • Multiple Myeloma • Plasmacytoma • PLAAT3

Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with Relapsed/Refractory multiple myeloma (ASH 2025) - P1 | "In cohortswithout (received 100 mg Q4W) and with (received 100 mg Q4W/Q8W) prophylactic tocilizumab, CRSoccurred in 69.2% (gr 2, 15.4%) and 20.0% (gr 2, 0%), respectively. With longer follow-up in part 1 of the phase 1 trial, JNJ-5322 continues to demonstrateresponses comparable to CAR-T therapy (ORR 100.0%) that are durable and continue to deepen (≥CR77.8%), with a safety profile similar or improved compared with BsAbs targeting BCMA or GPRC5D. JNJ-5322 offers off-the-shelf, Q4W dosing and 1 SUD with low rates of gr 2 CRS that may enable an efficientapproach to dual antigen targeting via convenient administration and outpatient treatment. Thesefindings support further evaluation of JNJ-5322 in patients with RRMM."

Clinical • IO biomarker • Trispecific • Infectious Disease • Inflammation • Multiple Myeloma • Neutropenia • Pneumonia • Respiratory Diseases

OL-101, a BCMA/GPRC5D dual-targeting autologous CAR-T for relapsed/ refractory multiple myeloma (R/R MM): Results from a Phase I study (ASH 2025) - P1 | "We report preliminary data from an ongoing phase I, first-in-human, dose-escalation and dose-expansion study (NCT06644118). Patients with R/R MM who had received ≥3 prior lines of therapies underwent standardlymphodepletion (fludarabine/cyclophosphamide) followed by a single OL-101 infusion at 3 dose levels(DL1: 1.0×106, DL2: 2.0×106, DL3: 1.5×106 cells/kg)...At the 2.0×106 cells/kg dose level, 1 of 6 patientsexperienced a DLT, manifested as grade 4 CRS with onset on Day 3 post-infusion, which resolved by Day17 following treatment with tocilizumab, steroids, plasma exchange and other supportive care... OL-101, a novel bispecific BCMA/GPRC5D VHH CAR-T, demonstrates promising efficacy (100%ORR, 100% MRD negativity) and manageable safety (CRS manageable, no ICANS) in heavily pretreated,triple-class exposed R/R MM patients, with no new safety signals identified than those with previouslyreported BCMA or GPRC5D targeting CAR-T cells. Notably,..."

IO biomarker • P1 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Neutropenia • Plasmacytoma • Thrombocytopenia • GPRC5D

Fixed-duration teclistamab and talquetamab for frail patients with newly diagnosed multiple myeloma: The EMN37 fitfix study (ASH 2025) - "The combination of daratumumab with bispecific antibodies may lead to deeper and moredurable responses that could enable a lenalidomide- and a dexamethasone-sparing regimen including atreatment-free interval (TFI) in the first-line therapy of frail NDMM patients...However, noformal comparison of efficacy or safety between Tec-Dara and Tal-Dara will be performed.To mitigate the risk of potential side effects, dose modifications and adequate supportive care areplanned, including prophylactic tocilizumab administration and prophylactic intravenousimmunoglobulin (IVIG) supplementation therapy.The study will be conducted in Italy (14 sites), the Netherlands (9), Spain (4), and Norway (2)...Theupdated status of the study will be presented at the meeting.The study is conducted by the European Myeloma Network (EMN), in collaboration with HOVON, NMSG,EMN Italy, and PETHEMA and in collaboration with and with the financial support of JanssenPharmaceutica NV, a member of the Johnson..."

Clinical • Hematological Malignancies • Multiple Myeloma

Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): Preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010 (ASH 2025) - "Tocilizumab was administered prophylactically in the latter two patients after the first IRR was observed...No clinical sequelae of the lymphocytosis were noted; dexamethasone promptly resolved the lymphocytosis in the patient with the highest ALC... Preliminary results from the first three patients dosed in the inMMyCAR Phase 1 study of KLN-1010 demonstrate that promising clinical activity and manageable toxicities are feasible with an offthe-shelf in vivo CAR-T in MM. Lymphodepletion was not required for in vivo CAR-T cell generation and expansion in the peripheral blood. CRS was consistent with that seen with ex vivo CAR-T therapies, while cytopenias were notably limited and no treatment-emergent infections occurred."

First-in-human • Gene therapy • Late-breaking abstract • Minimal residual disease • P1 data • Preclinical • Residual disease • CNS Disorders • Dyslipidemia • Gene Therapies • Hematological Malignancies • Infectious Disease • Movement Disorders • Multiple Myeloma • Neutropenia • Parkinson's Disease • Thrombocytopenia

IL18-armored CAR T cells in relapsed/refractory B cell acute lymphoblastic leukemia (ASH 2025) - P1 | "NEJM 2025), and here we share our initial experiencetreating patients with R/R B cell acute lymphoblastic leukemia (ALL).MethodsIn a single center, first in human clinical trial utilizing huCART19-IL18 (NCT04684563), adult patients withR/R CD19+ ALL were eligible, including those with CNS disease and those with relapses after priorCART19, blinatumomab, and allogeneic transplant (alloHCT)...Subjects then receivedlymphodepleting (LD) fludarabine and cyclophosphamide followed by huCART19-IL18 infusion.ResultsAs of Aug...Subjects had a median of 5 (3-11) priorlines of therapy including alloHCT in 4 patients, blinatumomab in 4 (3 as salvage for post-alloHCT relapse),and brexucabtagene autoleucel in 2...Three patients received tocilizumab for CRS, and 1 received corticosteroids andanakinra for ICANS...All treated patients withadequate follow-up achieved early MRD-negative CR (including in the CNS), and there have been norelapses or deaths with a median follow-up of 15.1..."

CAR T-Cell Therapy • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • CNS Disorders • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • IL18

Glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with high-tumor burden follicular lymphoma: First results of a multicenter phase II trial (ASH 2025) - P2 | "G3 CRS (fever, hypoxia) developed in apt with lung involvement by lymphoma and resolved rapidly (<24 hours) after administration ofdexamethasone and tocilizumab. Glofit and obin has a manageable safety profile and is associated with high CMR rates among pts withpreviously untreated, high-tumor burden FL. Pre-treatment with 4 doses of obin appears to reduce therisk of CRS with no cases of G2 and 1 case of G3 CRS observed among 35 patients. These results supportfurther exploration of glofit in FL."

Clinical • P2 data • Cough • Dermatology • Follicular Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Marginal Zone Lymphoma • Musculoskeletal Pain • Neutropenia • Oncology • Pruritus • Respiratory Diseases

Phase II Interim Results for Rapcabtagene Autoleucel (YTB323) in Patients with First-Line, High-Risk Large B-cell Lymphoma (TCT-ASTCT-CIBMTR 2026) - P1/2 | "One pt developed immune effector cell- associated hemophagocytic lymphohistiocytosis-like syndrome (Gr 2), which resolved after tocilizumab and anakinra treatment. Single-dose rapcabtagene autoleucel showed promising initial efficacy and a manageable safety profile in pts with 1L HR LBCL. Immunophenotyping and efficacy data for the final pt population with longer follow-up (≥6 mo for most pts) will be presented. Understand the initial safety and efficacy of rapcabtagene autoleucel (YTB323) in patients with large B-cell lymphoma who have received frontline chemoimmunotherapy"

Clinical • P2 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Large B Cell Lymphoma • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Rare Diseases • Thrombocytopenia • BCL2 • BCL6

Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) (ASH 2025) - P1/2 | "Sixteen pts (46%) were previously treated with blinatumomaband 13 pts (37%) with inotuzumab...CRS management includedtocilizumab (70%), siltuximab (10%), corticosteroids (40%), tocilizumab plus corticosteroids (37%), andanakinra (7%)...Seven pts received supportive measures for ICANS,including dexamethasone (5 pts, 71%) and anakinra (3 pts, 43%)... Phase 1 results with long follow-up suggest rapcabtagene autoleucel is active with highcellular expansion, durable efficacy for DL2–DL4, and a manageable safety profile in adult pts with r/r B-ALL. DL3—at which 92% of pts achieved BOR of CR/CRi by 3 mo, with median DOR not reached after 22mo median follow-up—exhibited an acceptable balance of safety, efficacy, and cellular expansion."

Clinical • P1 data • Acute Lymphocytic Leukemia • Aplastic Anemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Leukemia • Neutropenia • Rare Diseases

Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial. (PubMed, J Clin Oncol) - P3 | "Mosun-Pola demonstrated superior efficacy verus R-GemOx, with significant improvements in both overall response rate and progression-free survival, and infrequent cytokine release syndrome events with a manageable safety profile.(Funded by F. Hoffmann-La Roche Ltd; ClinicalTrials.gov, NCT05171647)."

Journal • P3 data • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

Severe polyneuropathy in HIV-negative human herpesvirus 8-associated multicentric Castleman disease successfully treated with rituximab and liposomal doxorubicin. (PubMed, J Infect Chemother) - "He was initially diagnosed with idiopathic MCD and treated with tocilizumab; however, his condition was refractory and progressively worsened, with muscle weakness, distal sensory disturbance, and autonomic dysfunction. This led to rapid resolution of systemic inflammation, clearance of HHV-8 viremia, and marked improvement in both neurological symptoms and nerve conduction abnormalities. This case highlights that HHV-8-associated MCD can cause severe POEMS-like polyneuropathy even in HIV-negative patients and underscores the importance of distinguishing HHV-8-associated MCD from idiopathic MCD in patients who are refractory to interleukin-6-targeted therapy."

Journal • Epstein-Barr Virus Infections • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Pain • Rare Diseases • Respiratory Diseases • IL6

Critical Intestinal Perforations in Pediatric Immunocompromised Patients: A Case-Based Review. (PubMed, Pediatr Rep) - "Each patient was receiving high-dose corticosteroids and/or targeted biologic immunomodulators (ruxolitinib, anakinra, tocilizumab, eculizumab). In this population, subtle findings such as persistent gastrointestinal bleeding, feeding intolerance, or minor imaging abnormalities should prompt consideration of perforation. Early imaging and multidisciplinary review are essential for timely intervention and improved outcomes."

Journal • Bone Marrow Transplantation • Critical care • Gastroenterology • Gastrointestinal Disorder • Hemophagocytic lymphohistiocytosis • Immunology • Oncology • Pain • Pediatrics • Rare Diseases • Transplantation

Decoding the Cardiac Immune Microenvironment and Fibroblast Crosstalk in Radiotherapy Combined with Immunotherapy-Induced Cardiac Fibrosis Based on Single-Cell Transcriptomic Analysis. (PubMed, Adv Sci (Weinh)) - "Our study identifies fibroblast-immune cell interactions, particularly IL-6-mediated fibroblast-macrophage crosstalk, as a key mechanism in radioimmunotherapy-induced cardiac fibrosis. Tocilizumab, an IL-6R inhibitor, demonstrates therapeutic potential to attenuate this cardiotoxicity."

IO biomarker • Journal • Cardiovascular • Fibrosis • Immunology • Oncology • CCR2 • CD86

Brexucabtagene autoleucel (Brexucel) as a consolidation therapy in B-cell acute lymphoblastic leukemia (B-ALL) post HCVAD/minihcvd-inotuzumab-blinatumomab regimens: Initial Results of a prospective Phase 2 trial. (ASH 2025) - P1/2 | "Leukapheresis could be followed by further chemo-immunotherapy and then standard lymphodepletion (LD) with fludarabine-cyclophosphamide beforebrexucel infusion...Adverse events included cytokine release syndrome (CRS) in 8 (57%) pts (all grade 1); 3 pts neededsingle dose tocilizumab... From Dec 2024-July 31 2025, 28 pts have had leukapheresis,18 pts were infused and 14 pts with afollow-up (FU) >1 month post brexucel infusion were included in this report. The median age of theinfused pts was 35 years (range 19-77), and 5 pts (36%) were ³60 years of age. Ten pts (71%) receivedbrexcuel as FL consolidation therapy for adverse genomics, 3 FL pts (21%) had persistent (n=2)/recurrent(n=1) MRD, and 1 (7%) pt had R/R ALL."

Clinical • IO biomarker • P2 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Inflammation • Leukemia • KMT2A • TP53

CAR-T: an effective option in primary refractory patients. (PubMed, Recenti Prog Med) - "Below, we describe the case history of a 69-year-old female patient diagnosed with DLBCL, treated in 2024 with axi-cel for refractory disease to first-line with R-CHOP, after bridging therapy with PolaBR and associated radiotherapy...Patient treatment after infusion required the management of a CRS and ICANS requiring tocilizumab for CRS and subsequently dexamethasone for the ICANS, with rapid resolution of symptoms. This experience confirms the potential efficacy of axi-cel in a very extensive, symptomatic, and chemorefractory disease, and is very informative due to the specific immuno-effector T cell toxicities that occurred, both for the importance of their recognition and for the importance of their early treatment. These factors now ensure that safety considerations are no longer a barrier to offering the most effective treatment to this group of patients."

Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Beyond comorbidities: CAR-T as a safe and effective option in frail patients with second-line DLBCL. (PubMed, Recenti Prog Med) - "We report a 74-year-old man with high-risk DLBCL and multiple comorbidities, refractory to first-line treatment, who received axicabtagene ciloleucel. Despite high CIRS and HCT-CI scores, he only developed grade 1 CRS successfully managed with early tocilizumab and transient cytopenia, achieving durable complete remission at 14 months...Instead, dynamic parameters such as ECOG, mEASIX and CAR-HEMATOTOX better identify patients at risk. A priori exclusion of frail individuals may unjustly deny access to a potentially curative therapy."

Journal • Diffuse Large B Cell Lymphoma • Hematological Disorders • Oncology

Refractory macrophage activation syndrome in adult-onset Still's disease: response to interferon-γ blockade and JAK inhibition. (PubMed, BMJ Case Rep) - "Further escalation of therapy with tocilizumab and etoposide yielded insufficient, partial improvement. The patient was then discharged on a stable dose of ruxolitinib, anakinra and prednisone. This case illustrates the therapeutic challenges in managing refractory MAS and highlights the emerging role of targeted therapies such as emapalumab and JAK inhibitors in treatment-refractory cases."

Journal • Hematological Disorders • Hemophagocytic lymphohistiocytosis • Immunology • Musculoskeletal Pain • Oncology • Rare Diseases • Rheumatology • IFNG

Safety and tolerability of Intraventricular Infusion of B7-H3.CAR-T cells in Recurrent Glioblastoma (SNO 2025) - "No patients required ICU admission or treatment with anakinra or tocilizumab. Conclusion : Intraventricular administration of B7-H3.CAR-T cells demonstrated an acceptable safety profile with no dose-limiting toxicities. Encouraging preliminary efficacy signals include a 44% disease control rate and median overall survival of 10.2 months, supporting continued dose escalation in this trial."

CAR T-Cell Therapy • Clinical • IO biomarker • Brain Cancer • Glioblastoma • Solid Tumor • CD276

The Cases of Acute Necrotizing Encephalopathy Due to Human Herpes Virus-6. (PubMed, Pediatr Infect Dis J) - "These cases highlight the potential for HHV-6 to cause severe encephalopathy in immunocompetent children. Early recognition, neuroimaging, and cerebrospinal fluid polymerase chain reaction testing are essential for diagnosis. Combined antiviral and immunomodulatory therapies may improve outcomes by addressing both viral replication and neuroinflammation."

Journal • CNS Disorders • Epilepsy • Epstein-Barr Virus Infections • Inflammation

Case Report: Early-onset VEXAS syndrome with recurrent pulmonary inflammation and myelodysplasia: a diagnostic and therapeutic challenge. (PubMed, Front Immunol) - "Tocilizumab induced transient improvement, but disease relapse followed...This case represents one of the youngest patients reported with VEXAS syndrome and provides rare evidence of UBA1 mutation in pulmonary cells, supporting the concept of tissue-level clonal inflammation. It highlights the importance of considering VEXAS in younger patients with unexplained systemic inflammation, cytopenias, and non-infectious pulmonary infiltrates, and supports early genetic testing and multidisciplinary management."

Journal • Bone Marrow Transplantation • Cough • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Myelodysplastic Syndrome • Ocular Inflammation • Ophthalmology • Pneumonia • Respiratory Diseases • Scleritis • Transplantation

Tocilizumab-loaded nanoparticles block IL-6R and reduce edema after intracerebral hemorrhage. (PubMed, J Adv Res) - "Our findings demonstrate that PTPR NPs are an effective platform for targeted IL-6 receptor (IL-6R) blockade in ICH and suggest a potential for delivering biologics in other neuroinflammatory diseases."

Journal • Cerebral Hemorrhage • Hematological Disorders • Inflammation • IL6R

Experiences with real-world teclistamab administration in community and outpatient settings: a mixed-methods study of hematology providers. (PubMed, Curr Med Res Opin) - "Over a quarter of practices (29%) used tocilizumab prophylactically. Outpatient teclistamab SUD has been successfully implemented in real-world practice for appropriately selected patients. This study provides insights into real-world outpatient SUD, including in community practices, to inform providers seeking to implement similar models to improve patient access while reducing cost and resource burden."

Journal • Real-world evidence • Hematological Disorders • Hematological Malignancies • Inflammation • Multiple Myeloma • Oncology

A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: First pre-planned analysis (the REVIVE Study) (ASH 2025) - P2 | "Introduction Recently, subcutaneous (SC) daratumumab monotherapy (compared to active monitoring) has beenfound to significantly lower the risk of progression from high-risk smoldering multiple myeloma (SMM) toactive multiple myeloma (MM) or death and prolong overall survival (the AQUILA Trial)...One hour prior to the first step updose of Tec, patients receive a single dose of tocilizumab 8 mg/kg to prevent cytokine release syndrome(CRS)...Nounexpected safety concerns were identified. At the meeting, we will present updated data on clinicalefficacy including preliminary data on durability of MRD negative responses, i.e. sustained MRD negativity(clinicaltrials.gov NCT06100237)."

Combination therapy • P2 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Neutropenia • Pneumonia • Respiratory Diseases • Smoldering Multiple Myeloma